In the last trading session, 1.85 million Legend Biotech Corp ADR (NASDAQ:LEGN) shares changed hands as the company’s beta touched 0.19. With the company’s per share price at $36.29 changed hands at $0.8 or 2.25% during last session, the market valuation stood at $6.68B. LEGN’s last price was a discount, traded about -67.73% off its 52-week high of $60.87. The share price had its 52-week low at $27.34, which suggests the last value was 24.66% up since then. When we look at Legend Biotech Corp ADR’s average trading volume, we note the 10-day average is 1.72 million shares, with the 3-month average coming to 1.83 million.
Analysts gave the Legend Biotech Corp ADR (LEGN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.20. If we narrow down to specifics, the data shows that 0 out of 11 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended LEGN as a Hold, 11 felt it is a Buy and 0 rated the stock as Underweight. Legend Biotech Corp ADR’s EPS for the current quarter is expected to be -0.22.
Legend Biotech Corp ADR (NASDAQ:LEGN) trade information
Instantly LEGN was in green as seen at the end of in last trading. With action 5.80%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -18.74%, with the 5-day performance at 5.80% in the green. However, in the 30-day time frame, Legend Biotech Corp ADR (NASDAQ:LEGN) is 25.35% up. Looking at the short shares, we see there were 14.37 million shares sold at short interest cover period of 6.39 days.
The consensus price target for the stock as assigned by Wall Street analysts is 75, meaning bulls need an upside of 51.61% from its current market value. According to analyst projections, LEGN’s forecast low is 75 with 75 as the target high. To hit the forecast high, the stock’s price needs a -106.67% plunge from its current level, while the stock would need to soar -106.67% for it to hit the projected low.
Legend Biotech Corp ADR (LEGN) estimates and forecasts
Year-over-year growth is forecast to reach 63.03% up from the last financial year.
Consensus estimates given by 13 financial analysts project the company’s revenue in the current quarter to hit an average of 232.3M. 13 analysts are of the opinion that Legend Biotech Corp ADR’s revenue for the current quarter will be 270.1M. The company’s revenue for the corresponding quarters a year ago was 186.52M and 160.21M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 24.54%. The estimates for the next quarter sales put growth at 68.59%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 0.79%. The 2025 estimates are for Legend Biotech Corp ADR earnings to increase by 13.38%.
LEGN Dividends
Legend Biotech Corp ADR is expected to release its next quarterly earnings report on 2025-May-13.
Legend Biotech Corp ADR (NASDAQ:LEGN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.33% of Legend Biotech Corp ADR shares while 47.77% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 48.42%. There are 47.77% institutions holding the Legend Biotech Corp ADR stock share, with FMR LLC the top institutional holder. As of 2024-06-30, the company held 9.6503% of the shares, roughly 17.62 million LEGN shares worth $780.46 million.
PRICE T ROWE ASSOCIATES INC /MD/ holds the second largest percentage of outstanding shares, with 6.292% or 11.49 million shares worth $508.86 million as of 2024-06-30.
Among Mutual Funds, the top two as of Apr 30, 2025 were Fidelity Select Portfolios-Health Care Portfolio and AIM Investment Fd.s -Invesco Developing Markets Fd. . With 3.16 shares estimated at $114.83 million under it, the former controlled 1.72% of total outstanding shares. On the other hand, AIM Investment Fd.s -Invesco Developing Markets Fd. held about 1.61% of the shares, roughly 2.96 shares worth around $107.57 million.
